Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation

PloS One
Shenjie TangJianan Huang

Abstract

The treatment of patients with MDR- and XDR-TB is usually more complex, toxic and costly and less effective than treatment of other forms of TB. However, there is little information available on risk factors for poor outcomes in patients with MDR- and XDR-TB in China. We retrospectively analyzed the clinical records of HIV-negative TB Patients with culture-proven MDR- or XDR-TB who were registered from July 2006 to June 2011 at five large-scale Tuberculosis Specialized Hospitals in China. Among 1662 HIV-seronegative TB cases which were culture-positive for M. tuberculosis complex and had positive sputum-smear microscopy results, 965 cases (58.1%) were DR-TB, and 586 cases (35.3%) were classified as having MDR-TB, accounting for 60.7% of DR-TB. 169 cases (10.2%) were XDR-TB, accounting for 17.5% of DR-TB, 28.8% of MDR-TB. The MDR-TB patients were divided into XDR-TB group (n=169) and other MDR-TB group (non-XDR MDR-TB) (n=417). In total, 240 patients (40.95%) had treatment success, and 346 (59.05%) had poor treatment outcomes. The treatment success rate in other MDR-TB group was 52.2%, significantly higher than that in the XDR-TB group (13%, P<0.001). In multivariate logistic regression analysis, poor outcomes were associated wi...Continue Reading

References

Aug 31, 2007·Journal of Korean Medical Science·Jae Chol ChoiWon Jung Koh
Oct 31, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Hye-Ryoun KimJae-Joon Yim
Nov 30, 2007·Emerging Infectious Diseases·Giovanni Battista MiglioriUNKNOWN SMIRA/TBNET Study Group
Jan 4, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christie Y JeonLaura E Via
Apr 29, 2008·Emerging Infectious Diseases·Ming-Chih YuRuwen Jou
Jul 10, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yong Soo KwonWon-Jung Koh
Aug 9, 2008·The New England Journal of Medicine·Zhenyu Gong
Aug 16, 2008·American Journal of Respiratory and Critical Care Medicine·Doh Hyung KimTae Sun Shim
Aug 22, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Chih-Cheng LaiPo-Ren Hsueh
Nov 14, 2008·Archivos de bronconeumología·Domingo J PalmeroJosé A Caminero Luna
Jan 24, 2009·The European Respiratory Journal·K Kliiman, A Altraja
Feb 5, 2009·PloS One·Ming ZhaoQian Gao
Feb 27, 2010·The European Respiratory Journal·V LeimaneT H Holtz
Mar 3, 2010·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Payam TabarsiJose A Caminero
May 28, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Karen R JacobsonMegan B Murray
Aug 28, 2010·The Lancet Infectious Diseases·José A CamineroGiovanni Battista Migliori
Sep 2, 2010·Antimicrobial Agents and Chemotherapy·Julien PoissyNicolas Veziris
Feb 24, 2011·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·Jaya Ruth AsirvathamGeeta Chacko
Mar 12, 2011·Emerging Infectious Diseases·Yunfeng DengXin Ma
Jul 1, 2011·The Korean Journal of Internal Medicine·Jinwoo LeeJae-Joon Yim
Oct 18, 2011·Emerging Infectious Diseases·Max R O'DonnellNesri Padayatchi
Mar 14, 2012·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·X LiX Ma
Jun 8, 2012·The New England Journal of Medicine·Yanlin ZhaoYu Wang
Oct 25, 2012·Emerging Infectious Diseases·Dawei ShiGuofeng Zhu

❮ Previous
Next ❯

Citations

May 9, 2014·Current Diabetes Reports·Marit Eika Jørgensen, Daniel Faurholt-Jepsen
Jan 28, 2015·Proceedings of the National Academy of Sciences of the United States of America·Meenal DattaRakesh K Jain
Dec 24, 2015·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Mohsen A GadallahSahar Khalil Kandil
Jan 31, 2018·Antimicrobial Agents and Chemotherapy·Qingfeng WangNaihui Chu
May 6, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marva SeifertTimothy C Rodwell
Mar 24, 2017·The European Respiratory Journal·Mayara Lisboa BastosDick Menzies
Jun 1, 2014·International Journal of Mycobacteriology·Rumina Hasan
Jul 16, 2019·Journal of the Chinese Medical Association : JCMA·Li-Kuo HuangShi-Chuan Chang
May 21, 2020·The European Respiratory Journal·C Finn McQuaidRichard G White
Jan 22, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Shenjie TangZhanjun Zhang
Mar 23, 2018·Scientific Reports·Joel Philip SamuelsJames Cameron Johnston
Aug 8, 2020·Archives of public health = Archives belges de santé publique·Daniel Bekele KetemaMehari Woldemariam Merid
Apr 6, 2019·Open Forum Infectious Diseases·Eun Hye LeeYoung Ae Kang
Mar 21, 2019·Tuberculosis Research and Treatment·Tamary Henry LeveriKajiru Kilonzo
Feb 9, 2021·Journal of Clinical Tuberculosis and Other Mycobacterial Diseases·Joseph Baruch BalukuWilliam Worodria
Apr 5, 2021·European Journal of Medical Research·Ming-Wu ZhangSong-Hua Chen

❮ Previous
Next ❯

Software Mentioned

SPSS14

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.